PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paparwork Reduction A Substitute for Form 1449/A/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

of 4

1995, no persons are i	required to respond to a collection of inform	mation unless it contains a valid OMB control number
		nplete if Known
	Application Number	10/672,144
OSURE LICANT	Filing Date	September 26, 2003
	First Named Inventor	Tamarkin et al.
	Group Art Unit	1616
ту	Examiner Name	
	Attorney Docket Number	01994-0027(42893-292447)

				U.S. PATENT DOCUMENT		
Examiner	Cite No.	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JEA/		2,768,958		Stewart, et al.	10/30/1956	
Ti i		2,785,153		Locke, et al.	03/12/1957	
		3,145,144		Ando, et al.	08/18/1964	
		3,149,036		Woodhour, et al.	09/15/1964	
		3,269,912		Grafe	08/30/1966	
		3,399,263		Strazdins, et al.	08/27/1968	
		3,531,565		Webb, et al.	09/29/1970	
		3,577,523		Stolar, et al.	05/04/1971	
		3,651,211		Gillchriest, et al.	03/21/1972	
		3,819,820		Lorina, et al.	06/25/1974	
		3,919,413		Mebus	11/11/1975	
		3,983,228		Woodhour, et al	09/28/1976	
		4,016,252		Relyveld	04/05/1977	
		4,053,587		Davidson, et al.	10/11/1977	
	<u> </u>	4,069,313		Woodhour, et al.	01/17/1978	
		4,177,263	1	Rosenberg, et al.	12/04/1979	
		4,196,185		Focella, et al.	04/01/1980	
	_	4,197,237		Leute, et al.	04/08/1980 .	
		4,197,286		Rao	04/08/1980	
		4,213,964		Buckler	07/22/1980	
1/		4,215,036		Malley	07/29/1980	
V		4,218,436		Fitzpatrick	08/19/1980	

	FOREIGN PATENT DOCUMENTS									
			Foreign Patent Do			Date of Publication of	Pages, Columns, Lines,	Т		
Examiner Cite No.'	Office ³	Number ⁴	Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Τ°			
/JEA/		wo	91/02078		Peptide Technology Ltd	02/21/1991				
		EP	0 269 408		Genentech, Inc.	11/24/1987				
		FR	2 334 366		A.N.V.A.R.	07/08/1977				
		FR	2 533 827		A.N.V.A.R.	04/06/1984				
		UK	981,242		The Wellcome Foundation Limited	01/20/1965				
		EP	0 044 722		Board of Trustees of the Leland Stanford Junior Univ.	01/27/1982				
		EP	0 179 483		The Juridical Foundation	04/30/1986				
V		EP	0 667 398 A	2	Kyoto Dai-ichi Kagaku Co., Ltd.	8-16-1995				

Examiner		Date	
Signature		Considered	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Complete if Known

10/672,144

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

Sheet 2

INFORM STATE

MATION DICCLOSUDE	Filing Date	September 26, 2003
MATION DISCLOSURE	First Named Inventor	Tamarkin et al.
MENT BY APPLICANT	Group Art Unit	1616
(use as many sheets as necessary	Examiner Name	
of 4	Attorney Docket Number	01994-0027(42893-292447)

Application Number

				U.S. PATENT DOCUMENT	S	
Examiner Initials	Cite No.1	U.S. Patent Number	Cocument Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JEA/		4,329,281		Christenson, et al.	05/11/1982	
1		4,330,530		Baker	05/18/1982	
		4,332,787		Homcy, et al.	06/01/1982	
		4,339,437		Rosenberg, et al	07/13/1982	
		4,346,074		Gilmour, et al.	08/24/1982	
		4,487,780		Scheinberg	12/11/1984	
		4,578,270		Csizer, et al.	03/25/1986	
		4,594,325		Lundak	06/10/1986	
		4,608,252		Khanna, et al.	08/26/1986	
		4,624,921		Larrick, et al.	11/25/1986	
		4,624,923		Margel	11/25/1986	
		4,639,336		Jouquey, et al.	01/27/1987	
		4,657,763		Finkelstein	04/14/1987	
		4,693,975		Kozbor, et al.	09/15/1987	
		4,720,459		Winkelhake	01/19/1988	
		4,740,589		Moreno	04/26/1988	
	t	4,744,760		Molday	05/17/1988	
		4,753,873		Beltz, et al.	06/28/1988	
		4,812,556		Vahlne, et al.	03/14/1989	
1/		4,880,750		Francoeur	11/14/1989	
—W -	<u> </u>	4,906,564		Lyon, et al.	03/06/1990	

	FOREIGN PATENT DOCUMENTS								
			Foreign Patent D	ocument		Date of Publication of	Pages, Columns, Lines,		
	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Te	
/JEA/		EP	0 156 242		Ohtomo et al.	10/02/1985			
1/		wo	94/21288		Assay Research, Inc.	09/29/1994	•		
V	-	wo	96/04313		Immunomedics, Inc.	02/15/1996			
								÷	
								\Box	
		 							
			· · · · · · · · · · · · · · · · · · ·						

		1
Examiner	Date	
Signature	Considered	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it contains a valid OMB control number

		into 1 aperwark Neddecian Act of 1909, no persons are	Complete if Known		
Substitute for Form 1449/A/PTO			Application Number	10/672,144	
	MEAD	MATION DICOLOCUDE	Filing Date	September 26, 2003	
		MATION DISCLOSURE	First Named Inventor	Tamarkin et al.	
	STATE	MENT BY APPLICANT	Group Art Unit	1616	
(use as many sheets as necessary		use as many sheets as necessary	Examiner Name		
Sheet	3	of 4	Attorney Docket Number	01994-0027(42893-292447)	

		U.S. Patent Document		U.S. PATENT DOCUMENT	Date of Publication of	Pages, Columns, Lines, Where
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear
/JEA/		4,977,286		Nicolaou, et al.	12/11/1990	
		5,017,687		Vahlne, et al.	05/21/1991	
		5,019,497		Olsson	05/28/1991	
		5,035,995		Taguchi, et al.	07/30/1991	
		5,112,606		Shiosaka, et al.	05/12/1992	
		5,126,253		Shiosaka, et al.	06/30/1992	
		5,736,410		Zarling et al.	04/1998	
		5,874,226		Zeytinoglu et al.	02/1999	
		4,451,570		Royston et al.	05/1984	
V		4,882,423		Taguchi et al.	11/21/1989	
					·	
		1				
	-			1		

	FOREIGN PATENT DOCUMENTS									
		Fo	reign Patent Do			Date of Publication of	Pages, Columns, Lines, Where			
Examiner Initials	Cite No.1	Office ³	Number ⁴	Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	T		
								\vdash		
								\vdash		
								\sqcup		
		+-+-						\vdash		
	_									

	, · · · · · · · · · · · · · · · · · · ·	
Cumminas		
Examiner	Date	
Clamakina	I was a second of the second o	
Signature	Considered	
l	Concessor	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

		•	•	•	
			- ¢ A		
Sheet	4		OT 14		

Complete if Known				
Application Number	10/672,144			
Filing Date	September 26, 2003			
First Named Inventor	Tamarkin et al.			
Group Art Unit	1616			
Examiner Name				
Attorney Docket Number	01994-0027(42893-292447)			

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
/JEA/		Balkwill, et al., "The Cytokine Network," Immun. Today, Vol. 10, No. 9, pp. 299-304 (1989)	
		Coulombe et al., "Cytochemical Demonstation of Increased Phospholipid Content in Cell Membranes in	
		Chlorphrntermine-induced Phospholipidosis," The Journal of Histochemistry and Cytochemistry, Vol. 37, No. 2, pp. 139-147 (1989)	
		Fraker, et al., "Passive Immunization Against Tumor Necrosis Factor Partially Abrogates Interleukin 2 Toxicity," The Journal of Experimental Medicine, Vol. 170, pp. 1015-1020 (1989)	
	•	Goldstein, et al., "Cardiovascular Effects of Platelet-Activating Factor," <i>Lipids</i> , Vol. 26, No. 12, pp. 1250-1256 (1991)	
		Goodman & Gilman's, the Pharmacological Basis of Therapeutics, Ninth Edition, McGraw Hill, New York, (1996), Chapter 51, pages 1260-1261, 1293	
	-	Hashimoto, et al., "Action Site of Circulating Interleukin 1 on the Rabbit Brain," Brain Research, Vol. 540, pp. 217-223 (1991)	
		Hisamatsu et al., "Platelet Activating Factor Induced Respiratory Mucosal Damage", Lipids, Vol. 26, No. 12, pp. 1287-1291 (1991)	
		Hopkins et al.; "Early Events Following the Binding Epidermal Growth Factor to Surface Receptors on Ovarian Granulosa Cells", European Journal of Cell Biology, Vol. 24, pp. 259-265 (1981)	
		Kang et al.; "Ultrastructural and Immunocytochemical Study of the Uptake and Distribution of Bacterial Lipopolysaccharide in Human Monocytes:, Journal of Leukocyte Biology, Vol. 48, pp. 316-332 (1990)	
		Kirchner et al., "The Development of Neutralizing Antibodies in a Patient Receiving Subcutaneous Recombinant and Natural Interleukin-2", Cancer, Vol. 67, pp. 1862-1864 (1991)	
		Lanzavecchia, "Identifying Strategies for Immune Interventixon," Science, Vol. 260, pp. 937-944 (1993)	
		Morris et al., "Validation of the Biotinyl Ligand-Avidin-Gold Technique", The Journal of Histochemistry and Cyrochemistry, Vol. 40, No. 5, pp. 711-721 (1992)	
		Ohmann et al., "Expression of Tumor Necrosis Factor- Receptors on Bovine Macrophages, Lymphocytes and Polymorphonuclear Leukocytes, Internalization of Receptor-Bound Ligand, and Some Functional Effects," Lymphokine Research, Vol. 9, No. 1, pp. 43-58 (1990)	
		Paciotti, G.F., et al. "Interleukin-1 Directly Regulates Hormone-Dependent Human Breast Cancer Cell Proliferation In-Vitro," Mol. Endocrinol., Vol. 2, pp. 459-464 (1988)	
		Paciotti, G.F., et al. "Interleukin-2 Differentially Effects the Proliferation of a Hormone-Dependent and a Hormone-Independent Human Breast Cancer Cell Line in Vitro and In Vivo," <i>Anticancer Research</i> , Vol. 8, pp. 1233-1240 (1988)	
		Paciotti, G.F., et al. "Interleukin-1α Differentially Synchronizes Estrogen-Dependent and Estrogen-Human Breast Cancer Cells in the G ₀ /G ₁ I Phase of the Cell Cycle," <i>Anticancer Research</i> , Vol. 11, pp. 25-32 (1991)	
		Peters, et al., "Binding and Internalization of Biotinylated Interleukin-2 in Human Lynphocites, <i>Blood</i> , Vol 76, No. 1, pp. 97-104 (1990)	
		Roitt, et al., "The Cytokine Network" Immunology, Mosby, (Baltimore, MD) 3rd ed., p. 8.15 (1993)	
V		Tommi, et al., "Production of Anti-Platelet-Activating Factor Antibodies by the Use of Colloidal Gold as Carrier," Jpn. J. Med. Sci. Biol., Vol. 44, pp. 75-80 (1991)	

Examiner /Jon Eric Angell/	Date Considered	10/13/2007
----------------------------	--------------------	------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.